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Ornithine decarboxylase (ODC) is the key enzyme in the polyamine biosynthetic pathway. ODC levels
are controlled by polyamines through the induction of antizymes (AZs), small proteins that inhibit
ODC and target it to proteasomal degradation without ubiquitination. Antizyme inhibitors (AZIN1
and AZIN2) are proteins homologous to ODC that bind to AZs and counteract their negative effect
on ODC. Whereas ODC and AZIN1 are well-characterized proteins, little is known on the structure
and stability of AZIN2, the lastly discovered member of this regulatory circuit. In this work we ﬁrst
analyzed structural aspects of AZIN2 by combining biochemical and computational approaches. We
demonstrated that AZIN2, in contrast to ODC, does not form homodimers, although the predicted
tertiary structure of the AZIN2monomer was similar to that of ODC. Furthermore, we identiﬁed con-
served residues in the antizyme-binding element, whose substitution drastically affected the capac-
ity of AZIN2 to bind AZ1. On the other hand, we also found that AZIN2 is much more labile than ODC,
but it is highly stabilized by its binding to AZs. Interestingly, the administration of the proteasome
inhibitor MG132 caused differential effects on the three AZ-binding proteins, having no effect on
ODC, preventing the degradation of AZIN1, but unexpectedly increasing the degradation of AZIN2.
Inhibitors of the lysosomal function partially prevented the effect of MG132 on AZIN2. These results
suggest that the degradation of AZIN2 could be also mediated by an alternative route to that of pro-
teasome. These ﬁndings provide new relevant information on this unique regulatory mechanism of
polyamine metabolism.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction Ornithine decarboxylase (ODC) is the key biosynthetic enzyme thatPolyamines are small cationic molecules essential for cell
growth, proliferation, differentiation and apoptosis [1–4]. In mam-
mals, the intracellular polyamine levels are tightly controlled by
the regulation of different processes including their biosynthesis,
degradation and transport across the plasma membrane [5].converts ornithine into putrescine, which is the precursor for the
physiological polyamines, spermidine and spermine. Different
studies have revealed that ODC and polyamines play an important
role in the development of cancer [6–8]. ODC activity is highly
dependent on the intracellular polyamine concentrations, being
rapidly down regulated under high polyamine amounts, acting at
transcriptional, translational and post-translational levels [9].
Post-translational regulation of ODC is mainly mediated by the
action of a family of small proteins named antizymes (AZs), whose
synthesis is stimulated by increased polyamine levels [10]. AZs
bind and inhibit ODC and target it to proteasomal degradation
without ubiquitination [11,12]. Besides, AZs inhibit extracellular
polyamine uptake presumably by interacting with the polyamine
transport system [13–15]. In mammals, the family of AZs is com-
posed by three isoforms (AZ1-3), AZ1 being the most predominant
(A)
(B) (C)
Fig. 1. Biochemical studies of the AZIN2 quaternary structure in transfected cells.
(A) Left panel: Cross-linking analysis of transfected cell lysates of AZIN2 and ODC.
HEK 293T cells were transiently transfected with AZIN2-FLAG, ODC-FLAG, or co-
transfected with AZIN2-FLAG and AZ1, and the cell lysates were incubated with
1 mM bissulfosuccinimidylsuberate (BS3) for 1 h. The proteins were then separated
by SDS-PAGE, transferred onto PVDF membrane, which was then incubated with an
anti-FLAG antibody. Note that the band corresponding to AZIN2 monomers
disappears after cross-linking. Right panel (marked with an asterisk): AZIN2 blot
similar to that shown in the left panel, but using a longer exposure time to the
detection reagent. Note that the tag is now found in high molecular weight bands.
(B) Migration pattern of AZIN2-FLAG and ODC-FLAG under native conditions.
Samples were analyzed by non-denaturing PAGE, blotted to PVDF and probed with
an anti-FLAG antibody. (C) Size-exclusion chromatography of AZIN2-FLAG and
ODC-FLAG. AZIN2-FLAG or ODC-FLAG cell lysates were resolved by a gel ﬁltration
column (Zorbax GF-250) and fraction aliquots were analyzed by Western blot or
assayed for ODC activity. The arrowhead marks the elution fraction in which bovine
serum albumin (BSA) was eluted.
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isoforms are able to inhibit ODC and the polyamine uptake, only
AZ1 clearly induces ODC proteasomal degradation [11,18]. In fact,
there are controversial data on the capacity of AZ2 for targeting
ODC to degradation in vivo and in vitro [19–21], and recently it
has been reported that AZ3, a testis-speciﬁc isoform [22,23], is
unable to target ODC to degradation [21].
In addition to AZs, the ODC activity is also indirectly regulated
by a family of proteins named antizyme inhibitors (AZINs). These
proteins, closely related to ODC but without enzymatic activity,
also interact with antizymes, even more efﬁciently than ODC,
counteracting the effects of antizymes on ODC [24,25]. In mam-
mals, the AZIN family is formed by two members: AZIN1 and
AZIN2. AZIN1 is a ubiquitous protein that regulates intracellular
polyamine levels and cell growth [26–29]. Mice with disruption
of the AZIN1 gene die soon after birth [30]. On the other hand,
AZIN2 was ﬁrst found to be expressed in testis and brain [31,32],
but more recent analyses have indicated that it is also expressed
in speciﬁc type of cells and secretory tissues [33–36]. Although
the physiological role of AZIN2 is mostly unknown, there are data
suggesting that it is involved in cell growth, vesicular trafﬁcking,
secretion and spermiogenesis [36–39]. Interestingly, overexpres-
sion of AZIN2 has been observed in certain pathologies [40].
Numerous studies have demonstrated that ODC is enzymati-
cally active as homodimer [9,41,42], and that in solution there is
an equilibrium between the monomeric inactive form and the
dimeric one [41,43]. It is also well known that antizyme exerts
its negative effect on ODC activity by binding to the ODCmonomer,
preventing the formation of the active ODC dimer, and by targeting
the inactive ODC to the 26S proteasome, where ODC is degraded
without ubiquitination [11]. Initial studies based on the differential
afﬁnity for AZ between murine and trypanosomal ODC, led to the
identiﬁcation of the antizyme-binding element (AZBE), as a
sequence spanning the residues from 117 to 140 in mouse ODC
[44]. Subsequently, the analysis of the tertiary structure of ODC
revealed that this region is present in two a-helices included in a
TIM-like a/b-barrel domain, in which several basic residues are
exposed toward the surface [45,46]. On the other hand, although
AZIN1 has been crystallized as a dimer, it has been detected in a
monomeric state under physiological conditions [47]. Like ODC,
AZIN1 binds to AZs through the AZBE region but in this case the
binding to AZs makes AZIN1 more resistant against proteasomal
degradation, probably because AZs inhibit its ubiquitination [48].
The interaction between ODC or AZIN1 with AZ1 through the AZBE
region has been computationally predicted by docking, the models
being quite similar in both cases [49]. Although the amino acid
sequences of the AZBE region of ODC and AZIN1 are quite similar,
differences in residues 125 and 140 have been related with their
differential AZ-binding afﬁnity [50].
In comparison to ODC and AZIN1, little is known about the
molecular aspects of the interaction between AZIN2 and AZs, prob-
ably due to the lack of information on AZIN2 structure. In addition,
the limited information related to AZIN2 degradation and interac-
tion with AZs has been mostly obtained from in vitro assays. Due to
the potential relevance of AZIN2 in the physiology of differentiated
cells, the aim of this work was to analyze structural and functional
properties of AZIN2, and determine their impact on the interaction
with AZs and the stability of the protein.
2. Results
2.1. Biochemical studies demonstrate that AZIN2 exists as a monomer
For this purpose, we used HEK 293T cells transfected with
AZIN2-FLAG, and compared the results with those obtained forODC-FLAG under the same experimental conditions. Cross-linking
analysis clearly showed, as expected, the presence of ODC dimers
(Fig. 1A). In the case of AZIN2, the putative dimer band was not
detected. However, after the cross-linking reaction the monomer
band almost disappeared, detecting faint staining of bands corre-
sponding to higher molecular weight than the putative dimer
(Fig. 1A). Since AZIN2 is located in the endoplasmic reticulum-
Golgi intermediate compartment (ERGIC) and in the trans-Golgi
network (TGN) [39,51], these higher molecular weight bands
may correspond to cross-linked species of the AZIN2 monomer
with membrane proteins of these compartments, to which AZIN2
is likely to be associated. Interestingly, when AZIN2 was co-trans-
fected with AZ1, after cross-linking experiments the main band of
AZIN2 detected was mainly the monomer, probably due to the fact
that AZ1 prevents the binding of AZIN2 to proteins of the outer
surface of the ERGIC or the Golgi apparatus, in agreement with pre-
vious data [39,51], and therefore, the formation of the cross-linked
species of higher molecular weight. To corroborate the monomeric
state of AZIN2 under physiological conditions, we next studied cell
extracts of transfected cells with AZIN2 (or ODC), using polyacryl-
amide gel electrophoresis (PAGE) under non-denaturing condi-
tions. Fig. 1B shows that whereas in the case of ODC two bands
were found, corresponding to monomeric and dimeric forms of
ODC, only the lower molecular weight band corresponding to the
monomer was detected for AZIN2. Finally, size exclusion chroma-
tography was used to analyze the size of transfected AZIN2 and
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AZIN2 were different. Thus, whereas ODC migrated mainly as a
dimer, AZIN2 was only found as a monomer.
Although all these results pointed out for the inability of
AZIN2 to form homodimers, in contrast to ODC, we wondered
whether AZIN2 may form heterodimers with ODC. To answer this
question we carried out immunoprecipitation assays using cells
co-transfected with constructs of AZIN2 tagged with the FLAG
epitope (AZIN2-FLAG) and ODC tagged either with the hemagglu-
tinin epitope (ODC-HA) or the FLAG epitope (ODC-FLAG). Fig. 2A
shows that in cells co-transfected with both ODC constructs,
dimers formed by ODC-HA and ODC-FLAG monomers could be
detected by Western blotting after co-immunoprecipitation. How-
ever, no evidence of heterodimer formation between AZIN2 and
ODC was found in the cells co-transfected with AZIN2-FLAG and
ODC-HA. In agreement with these results, ODC activity was not
decreased by co-transfection with AZIN2 (Fig. 2B). Note that the
formation of AZIN2-ODC heterodimers would have decreased
the activity of ODC due to the lack of decarboxylating activity
of AZIN2 [32,52].
2.2. Prediction of the 3D structure of murine AZIN2 monomer by
homology modeling
The 3D structure of ODC, the rate-limiting enzyme of polyamine
biosynthesis, has been previously characterized in mouse, human
and Trypanosoma brucei [45,46,53]. In all cases the structure is
composed of two well-deﬁned domains: a TIM-like a/b-barrel,
formed by eight a-helices and eight b-strands, and a b-sheet
domain. Because ODC crystallized as a dimer, the residues involved
in the interface between monomers have been well characterized
[45]. In addition, the 3D structure of mouse AZIN1 has also been
recently determined [47]. Although AZIN1 crystallized as a dimer,
subsequent experiments demonstrated that AZIN1 exists as a
monomer in solution under physiological conditions [47]. Little is
known on the structure of AZIN2, the recently characterized ODC
paralogue [32], since no AZIN2 crystals have been obtained so
far. However, due to the high sequence similarity of AZIN2 to
ODC and AZIN1 (48% and 37% sequence identity, respectively),
AZIN2 is an excellent candidate to be modeled using the compara-
tive modeling approach.
Full-length sequence of murine AZIN2 was submitted to the
Genesilico Metaserver [54]. Protein fold-recognition methods
detected, as the closest relatives with known structures, the mouse
ODC (PDB: 7odc) and mouse AZIN1 (PDB: 3btn). Both template
structures exhibited segments missing in crystals, for which
coordinates were not available: loops 30–35, 158–168 and(A) (B)
Fig. 2. (A) AZIN2 is unable to form heterodimers with ODC. Cells were transfected
with ODC-HA or co-transfected with ODC-HA and AZIN2-FLAG or ODC-FLAG.
Samples from cell lysates were analyzed by Western blot using an anti-HA
antibody. In addition, samples were inmunoprecipitated (IP) with anti-FLAG afﬁnity
gel beads for 3 h. After washing, the eluted proteins were subjected to Western blot
analysis and incubation with an anti-HA antibody (lower row). ODC-FLAG but not
AZIN2-FLAG interacted with ODC-HA. The blots shown are representative of three
experiments. (B) ODC activity in cells transfected with ODC alone or in presence of
AZIN2.298–311 and last 37 residues in the C-terminus in ODC and the
N-terminus (residues 1–7), loops 160–167, 294–310 and 330–
334 and the last 13 residues in the C-terminus in AZIN1. To
increase the structural coverage, we carried out comparative
modeling using both templates. The preliminary model of AZIN2
was generated by using the automated protein modeling program
Modeller [54], and its local accuracy was predicted by MetaMQAPII
[55]. Two loops comprising residues 160-167 and 298–310, and 13
N-terminal residues were predicted to be poorly folded, hence the
model was subjected to local optimization, using de novo loop
modeling approach implemented in Reﬁner [56]. The resulting
ﬁnal model (Fig. 3A and B) obtained the LG score of 5.219 according
to ProQ [57], which indicates a potentially ‘‘extremely good
model’’, which is also in agreement with scores predicted by
GDT_TS (70.207) and RMSD (3.002) according to MetaMQAPII
assessment. Furthermore, another important domain for the
subcellular localization of AZIN2, the region formed by residues
70–110 [51], is also included between two helices and a b-strand
in the same a/b-barrel. The close proximity of these two domains
may explain that after binding to AZs, the interaction of AZIN2 with
the outer surface of the ERGIC membranes may be hindered. Fig. 3C
shows the predicted 3D structure of AZIN2 in which the residues
70–110 and 111–145 are highlighted in red and yellow, respec-
tively. Like ODC and AZIN1, in AZIN2 the AZBE region (111–145)
is mainly formed by two a-helices and one b-strand, all of them
included in a TIM-like a/b-barrel.
2.3. Mutational analysis reveals the inﬂuence of conserved residues in
the AZBE region of AZIN2 on the interaction with AZ1
Although we initially reported that AZIN2 interacts with the
three antizymes [32], little is known on the molecular aspects of
this interaction. In ODC, an important structural element for the
binding to antizymes is the AZBE domain. This region was early
identiﬁed by comparing trypanosomal ODC, an enzyme isoform
that is not regulated by AZ, with mouse ODC [44]. The AZBE site
spans from residues 117 to 140 of mouse ODC. In a previous work,
we found that the deletion of this sequence abolished the capacity
of AZIN2 to stimulate polyamine uptake, presumably because this
variant does not interact with AZs [58]. In order to determine the
residues of the AZBE region of AZIN2 implicated in the interaction
with AZs, we considered the ﬁve conserved amino acid residues
(K116, A124, E139, L140 and K142) of this region in mouse AZIN2
(Fig. 4A), previously deduced [59] by using a multi-alignment
sequence analysis of the AZBE region of AZIN2 orthologues and
those of corresponding paralogues provided by the ENSEMBL
genome database. Given that several conserved acidic glutamate
residues are present in the region of AZ1 necessary for the interac-
tion with ODC [60] and that the putative AZBE site of ODC contains
various basic residues, one might expect an electrostatic binding
between AZ1 and ODC. In agreement with this hypothesis, a recent
study has associated the electric charge of the AZBE site to the
interaction ODC-AZ1 [61]. In the case of mouse AZIN2 the total
charge of the putative AZBE site is +2, due to the presence of ﬁve
basic (K116, K122, K126, R130 and K142) and three acidic residues
(D135, E137 and E139) (see Fig. 4A). Note that two of the con-
served residues are positively charged lysines (K116 and K142)
that could interact electrostatically with the conserved glutamic
residues of AZ1. To determine the inﬂuence of the electric charge
on the interaction between AZIN2 and AZ, we ﬁrst speciﬁcally gen-
erated several AZIN2 variants by substituting conserved lysine or
glutamic residues by neutral uncharged alanines. Thus, we
obtained several single, double and triple substitutions in which
the electric charge was maintained (A124S; L140A; E139A/
L140A/K142A), reduced (K116A; K142A; K116A/K142A) or
increased (E139A; E139A/L140A) (see Fig. 4B).
(A) (B)
(C)
Fig. 3. Structural model of mouse AZIN2. The upper row presents the predicted model in the ribbon (A) and the surface (B) representation, colored according to the predicted
local deviation from the real structure (i.e., the predicted error of the model), as calculated by MetaMQAPII: blue indicates low predicted deviation of Ca atoms down to 0 Å,
red indicates unreliable regions with deviation >5 Å, green indicates intermediate values. (C) Predicted tertiary structure of AZIN2 in the ribbon representation with the AZBE
region in yellow and the N terminus region formed by the 70–110 residues in red. The side chains of the amino acids included in the AZBE region (111–145) were also shown
and colored according to the type of atom (red, oxygen; blue, nitrogen).
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out immunoprecipitation experiments using co-transfected cell
lysates. Fig. 5A shows that whereas the variants with single alanine
substitutions K116A (K1A) and K142A (K2A) clearly interacted
with AZ1, almost similarly as wild type AZIN2, a weak signal was
detected in the case of the variant bearing a double substitution
K116A/K142A (KK/AA), suggesting that the elimination of the posi-
tive charge in the AZBE region negatively affects the interaction of
AZIN2 with AZ1. Additionally, as expected, no signal was observed
for the AZBE-deleted variant, since this protein lacks the structural
domain responsible for AZ binding. In order to test if the electric
charge of the AZBE region is the only factor responsible for the
interaction or whether the electro neutral substitution of the con-
served residues may affect such interaction, we tested the binding
of AZ1 to a variant with a triple substitution E139A/L140A/K142A
(ELK/AAA). In this variant the conserved residues E139, L140 and
K142 had been substituted by alanines, but it still retains a net
charge of +2 in the AZBE region. As shown in Fig. 5A the binding
of this variant to AZ1 was markedly lower than in the case of the
wild type or the single-substitution variant. This result suggests
that not only the charge but also the presence of critical conserved
residues are important for the interaction of AZIN2 with AZ1.
To conﬁrm this hypothesis, we generated additional protein
variants by substituting individually the residues E139 and L140
for alanines, and A124 for serine. We also obtained a variant with
a double substitution E139A/L140A (EL/AA) in order to determine
the importance of both residues respect to the variant with the tri-ple substitution ELK/AAA in which K142 was also substituted. The
effect of these substitutions on the AZIN2-AZ interaction was
tested by immunoprecipitation experiments (Fig. 5B). The variant
A124S markedly interacted with AZ1, similarly to the wild type
protein, ruling out an important role for this residue in the binding
to AZ1. The single substitutions of E139 and L140 residues to ala-
nines only moderately reduced the interaction with AZ1. However,
the variant EL/AA with a double substitution showed weaker inter-
action with AZ1 than the single-substitution variants but higher
than the triple-substitution variant ELK/AAA. It should be noted
that the variants E139A and EL/AA, although bearing an electric
charge of +3, did not show increased afﬁnity to AZ1. This suggests
again that the substitution of two or more conserved residues in
AZIN2 appears to be a more important factor than the reduction
of the positive charge to interact with AZ1.
2.4. Substitutions of conserved residues in the AZBE region affect the
biochemical functions of AZIN2
It is well known that AZIN2 increases ODC activity and poly-
amine uptake through the inhibition of endogenous AZ
[32,37,52,58]. In order to conﬁrm that the decreased AZ1-binding
capacity shown by the described substitutions also affected AZIN2
functions, we transiently transfected HEK 293T and COS7 cells
with the different constructs and the effects of these mutant forms
of AZIN2 on ODC activity and polyamine uptake were studied.
Fig. 6A shows that whereas wild type AZIN2 markedly increased
(A)
(B)
Fig. 4. Conserved residues of the putative AZBE region of mouse AZIN2. (A) Region encompassed by residues 117–143 of mouse AZIN2, showing the invariant residues
(shown in blue) found by multiple alignment of the AZBE amino acid sequences from different AZIN2 orthologues and paralogues (ODC and AZIN1). See Ref. [59]. (B)
Scheme of the different mutations in AZIN2 affecting the conserved residues of the AZBE region, and the electric charge of this region in the different AZIN2 mutants.
Fig. 5. Mutations of certain conserved residues of the AZBE region negatively affect the interaction of AZIN2 with AZ1. (A) HEK 293T cells were transfected with wild type
AZIN2-FLAG (AZIN2Wt), or with variants with single substitutions (K116A and K142A), double substitutions (KK/AA), triple substitutions (ELK/AAA) or with the AZBE-deleted
protein (DelAZBE), together with AZ1-HA. (B) Cells were transfected with AZIN2Wt or variants with single substitutions (A124S, E139A and L140A), double substitutions (KK/
AA and EL/AA), and triple substitutions (ELK/AAA), together with AZ1-HA. The cell lysates were immunoprecipitated with anti-FLAG afﬁnity gel beads for 3 h. After washing,
the eluted proteins (IP) were separated by electrophoresis and Western blot analysis was performed. AZ1-HA was detected using an anti-HA antibody.
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the double-substitution variant KK/AA and the triple-substitution
variant ELK/AAA, with reduced AZ-binding capacity, were not ableto increase the endogenous ODC activity. In another set of experi-
ments, using single, double and triple co-transfections with ODC,
AZ1 and different constructs of AZIN2, similar results were
Fig. 6. AZIN2 variants were less effective than unaltered AZIN2 in regulating the
polyamine homeostasis. (A) Inﬂuence of AZIN2 and its variants on the endogenous
ODC activity of HEK 293T cells. The cells were transiently transfected with AZIN2
(WT) or with some AZIN2 variants. Twenty-four hours after transfection ODC
activity was assayed in the cell extracts as indicated in Section 4. Control cells were
transfected with the empty vector. (B) Inﬂuence of AZIN2 and its variants on ODC
activity in cells co-transfected with ODC and AZ1. ODC and AZIN2 protein levels
were analyzed by Western blot. The molar ratio of the different constructs (ODC-
FLAG/AZIN2-FLAG/AZ) was 10:10:1. (C) Putrescine uptake by COS7 cells transfected
with AZ3 or co-transfected with AZ3 and AZIN2 variants. Control cells were
transfected with the empty vector. Data are expressed as mean ± S.E. of triplicate
determinations.
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the effect of AZ1 on ODC activity and protein, neither the KK/AA
variant nor the ELK/AAA variant were able to abrogate the effect
of AZ1 on ODC. Finally, the effect of AZIN2 and these variants on
putrescine uptake was assayed in COS7 cells transfected with
AZ3, because this antizyme isoform is probably an important phys-
iological partner of AZIN2, due to that both proteins are mostly
expressed in the testis [38]. Fig. 6C shows that in cells transfected
with AZ3, putrescine uptake was markedly reduced and that only
wild type AZIN2, but not the mutated forms of AZIN2, counteracted
the negative effect of AZ3 on polyamine transport. These resultsindicate that the changes elicited by these substitutions in AZIN2,
similarly affect the interaction of AZIN2 with both antizymes, and
concomitantly the AZIN2-mediated modulation of both ODC activ-
ity and polyamine uptake.
2.5. Half-life and degradation of AZIN2. Inﬂuence of the interaction
with AZs
To determine the half-life of AZIN2 and to compare this with
those of ODC and AZIN1, we transiently transfected HEK 293T cells
with constructs encoding the FLAG-tagged tested proteins, and
after transfection the cells were incubated with cycloheximide at
different times. Fig. 7A shows that under overexpression condi-
tions the half-life of AZIN2 (90 min) was much lower than that
of ODC (>8 h), but signiﬁcantly higher than that of AZIN1
(40 min). Note that transfected ODC was quite stable in contrast
to the short half-life (lower than 30 min) found for the endogenous
ODC of HEK 293T cells (data not shown), probably due to the
marked differences in the ODC/AZ ratio between transfected and
non-transfected cells. In addition, we analyzed the effect of AZs
on AZIN2 stability by means of the co-transfection of HEK 293T
cells with AZIN2-FLAG and each of the three different AZs.
Fig. 7B shows that the degradation of AZIN2 was reduced by the
presence of any of the three AZ isoforms, but the protective effect
was higher in the case of AZ1 and AZ2 (t1/2=543 ± 93, 492 ± 99 and
155 ± 10 min in presence of AZ1, AZ2 and AZ3, respectively).
Accordingly, the AZIN2 steady state levels were always higher in
presence of the AZs (Fig. 7C), which is in agreement with previous
works [37,38]. Although it is known that AZs are able to bind and
regulate ODC [18,24], and as shown here AZs stabilize AZIN2, little
is known on the effect of AZ-binding proteins on AZs stability.
Fig. 8A shows that the co-expression of AZIN2 with each of the
three AZs, markedly increased the steady state levels of AZs in
the transfected cells, and that such stabilization of AZs was not
observed when the cells were transfected with AZBE-deleted
AZIN2, a mutated form of AZIN2, that, as shown in Fig 5A, is unable
to bind to AZs. These results suggest that AZs and AZIN2 mutually
stabilize each other by the formation of an AZ-AZIN2 complex.
Similarly to AZIN2, ODC stabilized AZ2 and AZ3 but, however,
the effect on AZ1 was different since ODC elicited the decrease of
AZ1 protein. This discrepancy appears to be related with the deg-
radation of ODC by the proteasome, since the co-transfection of
AZ1 with the truncated form of ODC, lacking the 21 residues of
the C-terminal region (DCt-ODC), a stable form of ODC [9], pro-
tected AZ1 from degradation as efﬁciently as AZIN2 (Fig. 8C).
It is known that AZINs are degraded in a ubiquitin-dependent
manner by the proteasome [37,48,52], in contrast to ODC that is
degraded by the proteasome without ubiquitination [11]. To obtain
further information about possible differences in the degradative
processes of these proteins, we incubated HEK 293T cells, transfec-
ted with the different paralogue constructs, with cycloheximide in
absence and presence of the proteasome inhibitor MG132. Fig. 9A
shows that the protein levels of AZIN1 and AZIN2 decreased after
treatment with cycloheximide, as expected, due to the high turn-
over of these two proteins. However, the co-administration of
cycloheximide with the proteasomal inhibitor MG132 caused dif-
ferential effects on AZIN protein levels. Thus, whereas AZIN1 was
not decreased under this condition, due to the inhibitory effect of
MG132 on degradation, AZIN2 was still degraded. This unexpected
effect of MG132 on AZIN2 was corroborated by incubating AZIN2-
transfected cells with MG132 alone (Fig. 9B). To determine
whether the down-regulation of AZIN2 by the proteasome inhibi-
tor could be mediated by channeling AZIN2 to an alternative deg-
radative route to that of the proteasome 26S, we performed a set of
experiments in which the AZIN2-transfected cells were incubated
simultaneously with MG132 and different inhibitors of lysosomal
(A)
(B)
(C)
Fig. 7. Half-lives of AZIN2 and its paralogues ODC and AZIN1 in HEK 293T cells. (A) Cells were transfected with AZIN2, AZIN1 or ODC tagged with FLAG. Twenty-four hours
after transfection, cycloheximide (100 lM) was added, the cells harvested at the indicated times and ODC levels were detected by measuring the enzymatic activity, whereas
AZIN1 and AZIN2 protein levels were determined by Western blot analysis using an anti-FLAG antibody. (B) Inﬂuence of the AZs in the half-life of AZIN2. Cells were
transfected with AZIN2-FLAG alone or co-transfected with AZIN2-FLAG and each of the three AZ isoforms. Transfected cells were treated as indicated above and protein levels
were determined by Western blot analysis and incubation with anti-FLAG antibody as shown in (C). The indicated values of % degradation represent a mean value of three
repetitions.
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in Fig. 9C, the inhibition of the lysosomal degradation pathway
by ammonium chloride or chloroquine partially prevented the deg-
radation of AZIN2.
3. Discussion
Although antizyme inhibitors (AZIN1 and AZIN2) and ODC share
both high sequence similarity and the capacity to bind to anti-
zymes, there are many differences between these three homolo-
gous proteins. Thus, whereas ODC has ornithine decarboxylating
activity, antizyme inhibitors do not display any catalytic activity
[26,32]. In addition, ODC is one of the few mammalian proteins
that are degraded by the proteasome without ubiquitination [62],
while antizyme inhibitors require ubiquitination [37,48]. The
knowledge of the tertiary and quaternary structures of proteins
is fundamental to understand their mechanism of action. Thus, in
mammalian cells, monomeric and dimeric forms of ODC are in
equilibrium, but only the homodimer is catalytically active [41].
In addition, only the ODC monomer is able to bind to antizymes,
this step being required for its degradation by the proteasome
[12]. Although the crystal structures of ODC and AZIN1 have been
elucidated [45–47], and both ODC and AZIN1 crystallize as dimers,
AZIN1 exists only as a monomer in solution [47].Our results indicate that AZIN2 is mainly present as a monomer,
at least in transfected cells. The cross-linking experiments also
support that the AZIN2 monomer may be in close contact with
other cellular proteins. These ﬁndings are in agreement with previ-
ous experiments that showed that AZIN2 is associated to mem-
branes of the Golgi network [39,51]. In addition, the fact that co-
transfection with AZ1 prevented the cross-linking of AZIN2 with
such membrane proteins, may also be explained by considering
that the binding to AZ1 precludes the interaction of AZIN2 with
these target proteins, as suggests a preliminary docked model of
the AZIN2-AZ1 complex, in which the binding of AZ1 to the AZBE
domain may compete with the binding of AZIN2 to the mem-
branes, because the partial overlapping of these two AZIN2
domains (Ramos-Molina et al., unpublished data). This is also in
agreement with reported experiments in which the co-transfection
of AZIN2 with antizymes shifted AZIN2 from the membranous
structures to the cytosol [51]. Although our immunoprecipitation
studies also indicate that AZIN2 binds to AZ1, and that this binding
protects AZIN2 against degradation, we were not able to identify
the putative heterodimer AZIN2-AZ1 by the cross-linking experi-
ments. This could be due to the fact that in such complex the res-
idues that can react with the cross-linking agent are not located at
the adequate distance to allow the formation of bridges between
both proteins. Interestingly, the incapacity of AZIN2 to form
Fig. 8. AZIN2 expression increases the stability of the three antizymes in HEK293
cells. (A) Cells were transiently transfected with each AZ-HA alone, or together with
wild type AZIN2 or AZIN2 with deletion of the AZBE region (AZIN2DAZBE). Twenty-
four h after transfection, cells were lysed and AZ-HA levels were determined by
Western blot analysis, using an anti-HA antibody. (B) ODC stabilizes AZ2 and AZ3
but promotes AZ1 degradation. HEK293 cells were transfected with each AZ-HA
alone, or together with ODC or AZIN2. AZ expression was analyzed as in A. (C)
Differential effect of ODC and C-terminal truncated ODC (DCtODC) on AZ1 stability
in 293 cells. Cells were transiently transfected with each AZ-HA alone, or together
with ODC, DCtODC or AZIN2. Twenty hours after transfection, cells were incubated
with cycloheximide (100 lM) for 90 min, and after cell lysis AZ1-HA levels were
analyzed byWestern blotting, using an anti-HA antibody. Results are representative
of three separate experiments. Fig. 9. Effect of the administration of the proteasome inhibitor MG132 on the
protein levels of AZIN2 and its paralogues. (A) HEK 293T cells transiently
transfected with ODC-FLAG, AZIN1-FLAG or AZIN2-FLAG for 20 h were treated
with 100 lM cycloheximide alone or in combination with 50 lM MG132 for
additional 4 h. Protein levels were determined by Western blotting and incubation
with anti-FLAG antibody. Loading controls were performed using anti-Actin
antibody. (B) Twenty hours after transfection of the 293 cells with AZIN2-FLAG,
cells were incubated with different doses of MG132 dissolved in DMSO or DMSO
alone for additional 4 h, and the expression of AZIN2 was analyzed as described in
B. (C) HEK 293T cells transfected with AZIN2-FLAG were incubated for 5 h with no
inhibitor or with the proteasomal inhibitor MG132 (50 lM) alone or in combination
with inhibitors of lysosomal degradation (ammonium chloride 50 mM, chloroquine
200 lM). (D) HEK 293T cells transfected with AZIN2-FLAG were incubated for 5 h
with ammonium chloride (50 mM) or MG132 (50 lM) alone, and with a combi-
nation of both compounds. AZIN2 protein levels were assayed as in B. Actin was
determined as a loading control. Results shown are representative of at least three
separate experiments.
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negative dominant effect on ODC activity. Whereas ODC may form
dimers and AZIN1 may exist as a monomer physiologically [47],
our results have shown that AZIN2 is also a monomer. The different
ability of ODC and AZIN1 to form dimers has been explained by the
existence of substitutions of four essential residues in the putative
interface dimer of AZIN1 [63]. However, in the case of AZIN2 these
residues are similar to those of ODC, despite the fact that AZIN2 is a
monomer. This suggests than in AZIN2 other structural elements
must be responsible for its inability to dimerize.
The 3D structure of AZIN2 was predicted by comparative mod-
eling, using known structures of ODC and AZIN1 as templates. As
expected, the ﬁnal model was very similar to those of mouse
ODC and AZIN1, mainly in the two main domains (TIM-like a/b-
barrel and b-sheet), but differed considerably in the less conserved
regions including the N-terminus, C-terminus and some of the
loops. In this regard, it should be mentioned that a segment in
the N-terminal region of AZIN2 is required for its interaction with
the Golgi membranes [51], and that in ODC the C-terminal
sequence is critical for the interaction with the proteasome in
the antizyme-induced degradation of this enzyme [18].
The comparison of the AZBE regions of the different AZIN2
orthologues recently revealed the existence of seven conserved
residues, ﬁve of which were equally conserved in the ODC and
AZIN1 orthologues (three charged residues K116, K142 and E139;
and two non-charged residues A124 and L140) [59]. In the case
of mouse AZIN2 the net electric charge of the AZBE region is +2.
Given that in previous reports it was postulated that ODC and AZ
might interact electrostatically [46,61], the possible inﬂuence of
the electric charge of the AZBE region of mouse AZIN2 on its inter-
action with AZ1 can be evaluated from our results with the differ-
ent variants, in which the conserved residues and hence theelectric charge had been modiﬁed. According to our data, the sub-
stitution of only a single conserved residue of the AZBE region of
AZIN2 does not importantly affect the interaction with AZ1, inde-
pendently of the inﬂuence of the substitution on the electric charge
of AZBE (decreased in the case of K116A or K142A, maintained in
A124S, or increased in E139A). However, double or triple substitu-
tions of conserved residues markedly decreased the interaction of
AZIN2 with AZ1, independently of the effects of substitutions on
the net electric charge of the AZBE region. These results suggest
that charged conserved residues in the AZBE region of AZIN2 are
important for the interaction with AZs, independently of the net
charge of the region. In this regard, we recently demonstrated that
conserved lysines in the AZBE site of ODC are not relevant for the
interaction with AZ1 [59]. Remarkably, whereas the substitution
of Leu139 impaired critically the function of ODC, affecting the
dimerization and the catalytic processes, as well as the interaction
with AZs, in the case of AZIN2 the change of this Leu was not crit-
ical for the function and the binding to AZs. This discrepancy could
be explained by the differences existing in the adjacent residues
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was surrounded by numerous hydrophobic residues, suggesting
the existence of a hydrophobic pocket [62], in the case of AZIN2
this leucine not only was surrounded by hydrophobic amino acids
but also by two polar residues, Met and Ser (Fig. 10). These ﬁndings
suggest that the hydrophobic interactions might be less important
in the case of AZIN2, and, therefore, the substitution of this leucine
residue is not quite critical for the function of this protein.
The study on the metabolic stability and degradation of AZIN2,
and its comparison with those of ODC also showed clear differ-
ences between these two homologous proteins. AZIN2 was much
more unstable than ODC and, unlike ODC, the presence of any of
the three antizymes increased the metabolic stability of AZIN2.
Interestingly, AZIN2 also diminished the degradation of all anti-
zyme isoforms, this effect being dependent on the interaction of
antizymes with the AZBE region of AZIN2, since the deletion of this
segment in AZIN2 abolished the protective effect on AZs. ODC also
protected AZ2 and AZ3 against degradation but, however, it pro-
moted the degradation of AZ1. This difference could be related
with the major role of AZ1 on ODC degradation by the proteasome
in a ubiquitin-independent manner [11,12], in comparison to the
roles of AZ2 and AZ3 [19,21]. In addition, whereas it is known that
AZ1 is rapidly degraded through a mechanism that requires func-
tional ubiquitin-dependent proteolytic activity [64]), little is
known on the degradation of AZ2 and AZ3. Our data indicate that
these AZs are also very labile proteins, and that the binding to
either AZIN2 or ODC interferes with the degradative pathways of
these two AZs. In addition, although it is believed that AZ1 is not
degraded together with ODC when presenting the latter to the pro-
teasome [64], our present data suggest that AZ1 can be partially
degraded simultaneously to ODC degradation when the ODC-AZ1
complex interacts with the proteasome.
A remarkable difference between the degradative mechanisms
of ODC and AZINs is that, whereas the proteasomal degradation
of ODC is mediated by AZs in a ubiquitin-independent manner
[11,12], AZINs are degraded by the proteasome after ubiquitination
[37,48,52], having been demonstrated that AZ1 inhibits ubiquitina-Fig. 10. Visualization of key residues of the AZBE site in the 3D structure of mouse
ODC and AZIN2. The ﬁgure shows the residues found within a distance of 4 Å from
residues L139 and L140 in ODC (blue) and AZIN2 (orange), respectively. This image
was produced using UCSF Chimera from the data available in Protein Data Bank for
mouse ODC (PDB: 7ODC) and the ﬁnal model of AZIN2 generated by comparative
modeling. Residues were colored according to the type of atom (red, oxygen; blue,
nitrogen; yellow, sulfur).tion of AZIN1 [48]. The protective effect of the three AZs on AZIN2
degradation, shown here, could be exerted by inhibition of AZIN2
ubiquitination. All these facts would explain why when the levels
of the three ODC paralogues are higher than those of AZs, ODC is
more stable than AZINs. Although, as commented above, AZINs
appear to share a common degradative pathway, the differences
reported here on the half-lives of AZIN1 and AZIN2 and on the
effect of proteasome inhibitor MG132 suggest thatAZIN2 may be
also degraded by alternative routes to that of proteasome 26S, such
as through the lysosomal degradative pathway, which could gain
importance when the proteasomal pathway is inhibited. Similar
results have been reported for the degradation of other proteins
such as PTEN and IjBa [65,66]. Whether this difference between
AZINs may be related to the speciﬁc subcellular localization of
AZIN2 in ERGIC and vesicle-related structures [39,51] it remains
to be conﬁrmed.
In conclusion, our results indicate that AZIN2 is a monomeric
protein, with a 3D structure similar to those of ODC and AZIN1,
in which certain conserved residues are important for its interac-
tion with AZs. Like AZIN1, AZIN2 is a short-lived protein that is sta-
bilized upon its interaction with AZs, although under certain
conditions other proteolytic systems, besides the 26S proteasome,
might be involved in its degradation. Since recent studies have
indicated that AZIN2 may have a role in secretory cells
[33,36,39], the knowledge of structural aspects of the protein
may help to better understand the molecular mechanisms by
which AZIN2 may participate in secretion or in other cellular pro-
cesses where AZIN2 may be implicated.
4. Materials and methods
4.1. Materials
L-[1-14C] ornithine was purchased from Moravek Biochemicals
Inc. (Brea, CA). Anti-FLAG M2 monoclonal antibody peroxidase
conjugate, anti-HA monoclonal antibody peroxidase conjugate,
anti-FLAG afﬁnity gel beads, Igepal CA-630, cycloheximide, suberic
acid bis(3-sulfo-N-hydroxysuccinimide ester) sodium salt (BS3),
MG132 (Z-Leu-Leu-Leu-al) and chloroquine were obtained from
Sigma Aldrich. Lipofectamine 2000 transfection reagent, Dul-
becco’s Modiﬁed Eagle Medium (DMEM), glutamine, fetal bovine
serum (FBS) and penicillin/streptomycin were purchased from
Invitrogen (Carlsbad, CA). QuickChange site-directed mutagenesis
kit was from Stratagene (La Jolla, CA). [1,4-14C] Putrescine (speciﬁc
activity 107 mCi/mmol) was from Amersham Biosciences. Pierce
ECL Plus Western Blotting Substrate was from Thermo Scientiﬁc
(IL, USA). Primers were purchased from Sigma Genosys.
4.2. Protein structure prediction
Protein sequences were submitted to the GeneSilico metaserv-
er, which is a gateway to a large number of third-party methods
that facilitates comparison and interpretation of predictions made
by different algorithms [54]. In particular, the metaserver was used
for secondary structure prediction and for protein fold-recognition
(i.e. alignment of target protein sequence to proteins with experi-
mentally determined structures that can be used as templates for
modeling). Fold-recognition alignments reported by primary
methods were compared, evaluated, and ranked by the PCONS
method [67]. PCONS score >1 in general indicates estimation that
the protein fold has been correctly guessed by FR methods. How-
ever, lower scores do not necessarily exclude correct predictions,
in particular for folds with strongly diverged members. In such
cases, a good estimator of prediction quality is the number of
occurrences of a given fold at the top positions of the PCONS
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the top-scoring templates [PDB: 7odc (murine ODC) and PDB: 3btn
(murine AZIN1)] were used as a starting point for modeling of
AZIN2 tertiary structure comprising cycles of model building by
Modeller [69], evaluation by MetaMQAPII [55], realignment in
poorly scored regions as long as manual alignment changes does
not improve model quality. Uncertain regions (residues 160–170,
296–312, 342–349 and 418–459) were modeled de novo using
Reﬁner [56] in the context of ‘frozen’ remainder of the AZIN2
model. Coordinates of the model are available for download from
the metaserver (ftp://genesilico.pl/iamb/models/AZIN2/).
4.3. Protein model evaluation
For evaluation of models we used two Model Quality
Assessment Programs (MQAPs): MetaMQAPII [55] and PROQ [57].
It must be emphasized that MQAP scores only predict the deviation
of a model from the real structure (the real deviation can be calcu-
lated only by comparison to the real structure, which of course is
not available). Thus, the scores reported in this work that indicate
e.g. ‘extremely good models’, must be interpreted as estimations or
predictions that our models are ‘extremely good’, and not as
ultimate validation of the model quality. However, it should be
mentioned that both PROQ and MetaMQAPII performed very well
in various tests and can be regarded as robust predictors.
4.4. Cloning and plasmids
ODC and AZIN2 mouse genes were cloned into the expression
vector pcDNA3 (Invitrogen) following standard procedures and
the FLAG epitope was introduced to the N terminus of ODC and
AZIN2 as described previously [32]. The AZIN2-FLAG construct
with a deletion in the antizyme-binding site was generated by
PCR and subcloning into pcDNA3 plasmid containing the FLAG epi-
tope [58]. Antizyme constructs with an appropriate deletion of one
nucleotide in the frameshifting site, for full-length and functional
expression, were obtained by mutagenesis [32]. The HA-tagged
constructs ODC-HA and AZ1-HA were generated by introducing
the HA epitope to the N terminus of ODC and AZ1, respectively.
4.5. Site-directed mutagenesis
The AZIN2-FLAG construct cloned into the expression vector
pcDNA3 was used as template for site-directed mutagenesis using
the QuickChange site-directed mutagenesis kit. The AZIN2-FLAG
variants generated were K116A, K142A, K116A/K142A, A124S,
E139A, L140A, E139A/L140A and E139A/L140A/K142A. In the case
of truncated ODC ((DCtODC) a stop codon (TGA) was introduced in
the position corresponding to C441. All constructs were veriﬁed by
complete sequencing.
4.6. Cell culture and transient transfections
The monkey kidney ﬁbroblast-like COS7 and the human embry-
onic kidney (HEK) 293T cell lines were obtained from the ATCC.
Both cell lines were cultured in DMEM, containing 10% FBS,
100 units/ml penicillin, and 100 lg/ml streptomycin, in a humidi-
ﬁed incubator containing 5% CO2 at 37 C. Cells were grown to
80% conﬂuence. Transient transfections were carried out with
Lipofectamine 2000 transfection reagent using 1.5 ll of reagent
and 0.3 lg of plasmid per well (12-well plates) in the case of
HEK 293T cells and 1 ll of reagent and 0.15 lg of plasmid per well
(24-well plates) in the case of COS7 cells. In co-transfection exper-
iments, the mixtures contained equimolecular amounts of each
construct. After 6 h of incubation the transfection medium was
removed, and fresh complete medium was added, and cells werecultured for 24 h after transfection. The plasmid pcDNA3 without
gene insertion was used as negative control.
4.7. Western blot analysis
Transfected cells were collected in PBS, pelleted, lysed in solubi-
lization buffer (50 mM Tris–HCl (pH 8), 1% Igepal and 1 mM EDTA)
and centrifuged at 14000g for 20 min. Equal amounts of protein
were separated in 10% SDS-PAGE. Gels were transferred to PVDF
membranes, blocked with 5% nonfat dry milk in PBS-T (Tween
0.1%), and incubated overnight at 4 C with the anti-FLAG antibody
peroxidase-labeled (1:10000). Immunoreactive bands were
detected by using ECL+ detection reagent.
4.8. Cross-linking analysis
HEK 293T cells transfected with ODC-FLAG or AZIN2-FLAG were
lysed, and the lysates were incubated for 1 h at 25 C in 1 mM Tris–
HCl, pH 7.5, either alone or with 1 mM bissulfosuccinimidylsuber-
ate (BS3) as crosslinking agent. The cross-linking reaction was ter-
minated by the addition of 1 M Tris–HCl, pH 7.5. Then, the cross-
linked material was analyzed by Western blotting and incubation
with an anti-FLAG antibody.
4.9. Non-denaturing polyacrylamide gel electrophoresis (PAGE)
Cell lysates from HEK 293T cells transfected with ODC-FLAG
and AZIN2-FLAG were mixed in sample buffer (62.5 mM Tris–HCl
(pH 6.8), 25% glycerol and 1% bromophenol blue) and separated
by PAGE (running buffer and polyacrylamide gels without SDS) at
constant current (25 mA/gel) in a cold room until the bromophenol
blue reaches the bottom of the gel (about 2 h). Gels were then
transferred to PVDF membranes, blocked and incubated with an
anti-FLAG antibody.
4.10. Size-exclusion chromatography
HEK 293T cells transfected with ODC-FLAG or AZIN2-FLAG were
lysed in solubilization buffer and centrifuged at 14.000g for
20 min, being the supernatant directly injected into a Zorbax Bio
Series GF-250 column (Agilent Technologies, CA, USA) in a buffer
containing 50 mM Tris, 1 mM EDTA, 4 mM pyridoxal phosphate,
and 0.1% Igepal. Sixty 100-ll fractions were collected and analyzed
by Western blotting and incubation with anti-FLAG antibody.
Bovine serum albumin (Mr 66,000) was used as standard, but in
this case fractions were separated by SDS–PAGE and stained with
Commasie Blue.
4.11. Immunoprecipitation
HEK 293T cells were transfected with different AZIN2-FLAG
variants, alone or in combination with AZ1-HA. 1  106 cells were
collected in PBS and lysed in 100 ll of solubilization buffer. The
samples were centrifuged at 14000g for 20 min, and each super-
natant was immunoprecipitated by adding 20 ll of anti-FLAG
afﬁnity gel beads. After 3 h incubation, the sample was centrifuged,
and the pellet was washed three times with the same solubiliza-
tion buffer. Elution was performed in 20 ll of 2 electrophoresis
sample buffer for 30 min at room temperature. The eluted samples
were resolved by SDS–PAGE and analyzed by Western blot.
4.12. ODC activity assay
Transfected HEK 293T cells were collected in PBS, pelleted and
lysed in solubilization buffer. The extract was centrifuged at
14000g for 20 min, and ODC activity was determined in the
520 B. Ramos-Molina et al. / FEBS Open Bio 4 (2014) 510–521supernatant. ODC activity was assayed by measuring 14CO2 release
from L-[1-14C] ornithine [32].
4.13. Polyamine uptake assay
Transient transfected COS7 cells were washed with DMEM
(serum-free) and incubated with 200 ll of fresh DMEM (serum-
free) containing [1,4-14C] putrescine at a ﬁnal concentration of
2 lM. After incubation at 37 C for 20 min, the cells were washed
with cold PBS and lysed with trypsin at 37 C for 30 min. Finally,
3 ml of the scintillation solution was added, and the radioactivity
was measured. The nonspeciﬁc accumulation of [1,4-14C] putres-
cine was measured by incubation of the cells with the radioactive
compound for 20 min at 4 C.
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